All articles by GlobalData Healthcare

  1. Will the UK relax its current regulations for cannabis-based products?

    Recently medicinal cannabis has been at the forefront of media attention in the UK, and in July 2018 the UK…
    Read More…

    18 Sep
  2. Could Bristol-Myers Squibb change the psoriasis market?

    The psoriasis drug market is  fiercely competitive, and strongly held by large pharmaceutical companies that offer biological treatments. These treatments…
    Read More…

    14 Sep
  3. CAR-T toxicity rating system to be finalized by ASBMT by year-end

    The American Society of Blood and Marrow Transplantation (ASBMT) is in the process of developing a toxicity rating system for…
    Read More…

    11 Sep
  4. Why are novel therapies for glioblastoma patients not gaining approvals?

    Despite the abundance of approvals and launches of novel therapies in the oncology space, glioblastoma multiforme (GBM), a solid tumor…
    Read More…

    10 Sep
  5. Will tumor-agnostic drug development help accelerate precision medicine approaches?

    The first accelerated approval for a tumor-agnostic drug was granted by the FDA in May 2017, enabling patients with any…
    Read More…

    27 Jun
  6. Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market

    Roche announced on Monday, June 25 that the Phase III IMpower133 study evaluating its anti-programmed death-ligand 1 (PD-L1) immune checkpoint…
    Read More…

    26 Jun
  7. The challenges of using stem cells in neurology

    The development of stem-cell based therapies has been slow even though there are many theoretical applications and benefits associated with…
    Read More…

    25 Jun
  8. Another BACE inhibitor fails in phase III trials

    On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE)…
    Read More…

    20 Jun
  9. US biosimilar setbacks highlight difficulty of cost-effective development

    Complete response letters (CRLs) were issued by the FDA recently for two biosimilar versions of Roche’s Rituxan—first to Celltrion and…
    Read More…

    22 May
  10. PD-L1 biomarker makes a comeback in bladder cancer

    PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of…
    Read More…

    22 May